AzTrials
AzTrials

Any CancerPROACTNCT06479057

PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy

An observational study of Any Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care. This is an observational cohort study in the context of a quality-of-care initiative. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Any Cancer
What is being tested?
Supportive Care Pathway
How many people
700 participants
Where
1 siteFrance
Study dates
11 Jan 2024to Jul 2027
How long will I take part?
6 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient with any cancer type, any stage receiving supportive care interventions at Gustave Roussy. For the primary endpoint all the patients participating in supportive care pathways with formal supportive care needs assessment and targeted referrals will be invited to participate. For the secondary endpoints, any patient included in the supportive care interventions at the institution may participate.

Who may be able to join

  • Histological confirmation of cancer (any cancer type, any stage)
  • Age ≥ 18 years old
  • Received an integrated supportive care need assessment.
  • Sign the consent form for the PROACT study.

Who cannot join

  • Absence or inability of written consent from the patient.
  • Does not understand or speak French.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Gustave Roussy

    Villejuif, 94800

    Ines VAZ LUIS, INES-MARIA.VAZ-DUARTE-LUIS@gustaveroussy.fr

    Aude BARBIER, aude.barbier@gustaveroussy.fr

    Recruiting

Other trials in France

About this study

Official title: Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)

PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.

This is an observational cohort study in the context of a quality-of-care initiative.

It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.

Read the detailed description

The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.

Secondary study endpoints include:

  1. To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log)
  2. To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire)
  3. To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL)
  4. To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30)
  5. To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI)
  6. To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS)
  7. To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI)
  8. To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22)
  9. To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log)
  10. To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log)
  11. To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires.
  12. To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers)
  13. To plan for Maintenance of the pathway through a cost effectiveness analysis.
  14. To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population
  15. To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population
  16. To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population
  17. To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT)
  18. To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population.
  19. To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS)

This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.

Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).

Conditions
Any Cancer
Being tested
Supportive Care Pathway
Keywords
supportive care pathway, cancer, master protocol, supportive care, Distress
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supportive Care PathwayOther

    All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.

Study groups in NCT06479057
Study groupRoleWhat they receive
PROACT Supportive Care pathwaysThis is a prospective cohort study including patients participating in institutional supportive care pathways at diagnosis, during treatment and after treatment.
Receives: Other: Supportive Care Pathway

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patient distress

    Patient distress collected with NCCN Distress Thermometer

    Measured: over a 12-week period after the integrated supportive care needs assessment.

  2. Patient unmet needs

    Patient unmet needs collected with problem list from NCCN Distress thermometer

    Measured: over a 12-week period after the integrated supportive care needs assessment.

Secondary outcomes (21)
  1. Reach of the pathway

    Proportion of patients who accepted the supportive care needs assessment (descriptive numbers from attendance log)

    Measured: week 12

  2. Diversity of pathway participants

    Socioeconomic characteristics of participants in the pathway measure by a self-reported socioeconomic questionnaire

    Measured: week 12

  3. Impact of the pathway in overall health status

    Overall health status measured by the EQ-ED-5L

    Measured: week 12, and 24

  4. Impact of the pathway in Quality of life

    Quality of life measured by the EORTC QLQ C30

    Measured: week 12, and 24

  5. Impact of the pathway in symptom burden

    Symptom burden measured by the MDASI Questionnaire.

    Measured: week 12, and 24

  6. Impact of the pathway on anxiety levels

    Anxiety measured by HADS

    • only for patients reporting anxiety at baseline

    Measured: week 12, and 24

  7. Impact of the pathway on insomnia levels

    Insomnia measured by ISI

    *only for patients reporting insomnia at baseline

    Measured: week 12, and 24

  8. Impact of the pathway on sexual health

    Sexual health measured by EORTC SHQ-C22

    *only for patients reporting sexual dysfunction at baseline

    Measured: week 12, and 24

  9. Adoption of Physician

    Proportion of physicians referring patients to the supportive care pathway (descriptive numbers from referral logs)

    Measured: week 12

  10. Adoption of Patient

    Proportion and of patients that fully adopted each supportive care intervention (e.g.; in the after cancer pathway: attendance to consultations/seminaries/classes, completion of a supportive care program, usage data for Resilience app).

    Measured: week 12

  11. Patient Experience

    Patient experience measured by the PACIC questionnaire.

    Measured: week 12

  12. Patient Satisfaction with the pathway

    Patient satisfaction measured by an ad hoc satisfaction questionnaire

    Measured: week 12

  13. Provider Experience - Qualitative evaluation

    Focus groups with healthcare providers to explore overall experience, workload and implementation challenges

    Measured: week 12

  14. Patient Satisfaction/Experience - Qualitative evaluation

    Focus groups with patient to explore overall experience and implementation challenges

    Measured: week 12

  15. Maintenance of the pathway through a cost effectiveness analysis (QALYs)

    Maintenance of the pathway through a cost effectiveness analysis. Costs from the perspective of the French national health insurance will be assessed during the study period. This will be calculated by administrative data review of internal allocated resources for pathway delivery and estimated costs of use of hospital services (unplanned hospitalization, consultations, and emergency visits recorded in the electronic medical records).

    QALYs (quality-adjusted life years) will be measured using utility values derived from the EuroQol-5D (EQ-5D-5L) (https://euroqol.org/) for French general population (Andrade et al. PharmacoEconomics 2020). QALYs will be computed combining survival time by utility values.

    Measured: week 12

  16. Impact of the pathway on Intestinal Symptom

    Intestinal Symptoms measured by LARS score.

    *only for patients with digestive cancer

    Measured: week 24

  17. Impact of the pathway on Anal incontinence

    Anal incontinence measured by Wexner score.

    *only for patients with digestive cancer

    Measured: week 24

  18. Impact of the pathway on Urinary symptoms

    Urinary symptoms measured by USP score.

    *only for patients with digestive cancer

    Measured: week 24

  19. Impact of the pathway on Functional Assessment of Cancer Therapy-Bone Marrow Transplant

    Functional Assessment of Cancer Therapy-Bone Marrow Transplant measured by FACT-BMT score.

    *only for patients with Hematologic Cancer

    Measured: week 12, week 24

  20. Impact of the pathway on caregiver burden

    Caregiver burden measured by Montgomery Borgatta Caregiver Burden Scale.

    Measured: week 12

  21. Impact of the pathway on healthcare professionals participating in the pathway to screen vulnerability and prevent treatment

    Healthcare professionals measured by F-SUS Score

    Measured: week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2024
  2. Study start11 Jan 2024
  3. Primary completionJan 2027 (estimated)
  4. Study completionJul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
700 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06479057
Sponsor's protocol ID
2023-A01225-40
Other IDs
2023/3662
Acronym
PROACT
Status last verified
Jan 2026
First submitted
5 Apr 2024
Last updated
16 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Franzoi MA, Santolaya C, Martin E, Fasse L, Rouby P, Minot-This MS, Di Meglio A, Vaz-Luis I. "Let's talk about risk": co-designing a pathway to assess, communicate and act on individual risk of long-term toxicities after breast cancer. J Cancer Surviv. 2025 Jun 12. doi: 10.1007/s11764-025-01826-0. Online ahead of print.

    PubMed 40504480
  • Franzoi MA, Pages A, Papageorgiou L, Di Meglio A, Laparra A, Martin E, Barbier A, Renvoise N, Arvis J, Scotte F, Vaz-Luis I. Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study. JMIR Res Protoc. 2024 Aug 26;13:e52841. doi: 10.2196/52841.

    PubMed 39186774

Questions about this trial

What is this clinical trial studying?

An observational study of Any Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maria Alice BORINELLI-FRANZOI (+33 (0)1 42 11 42 11, Mariaalice.BORINELLI-FRANZOI@gustaveroussy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient distress (time frame: over a 12-week period after the integrated supportive care needs assessment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06479057, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in